(Q34087387)

30 July 2017

1 reference

title

Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

Martin Lagging

1

0 references

Ola Weiland

object named as

Ola Weiland

11

0 references

Ingrid Uhnoo

3

object named as

Ingrid Uhnoo

1 reference

30 July 2017

Rune Wejstål

2

1 reference

30 July 2017

Barbro Gerdén

4

1 reference

30 July 2017

Björn Fischler

5

1 reference

30 July 2017

Styrbjörn Friman

6

1 reference

30 July 2017

Filip Josephson

7

1 reference

30 July 2017

Olle Karlström

8

1 reference

30 July 2017

Per Sangfelt

9

1 reference

30 July 2017

Robert Schvarz

10

1 reference

30 July 2017

Swedish Consensus Group

12

1 reference

30 July 2017

1 January 2009

1 reference

Scandinavian Journal of Infectious Diseases

30 July 2017

1 reference

30 July 2017

41

1 reference

30 July 2017

6-7

1 reference

30 July 2017

389-402

1 reference

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

30 July 2017

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Hepatitis C virus-related lymphoproliferative disorders: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Chronic hepatitis C: updated Swedish consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Characteristics of patients with dual infection by hepatitis B and C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Duration of peginterferon therapy in acute hepatitis C: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Alcohol use and treatment of hepatitis C virus: results of a national multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Community-based seroepidemiological survey of HCV infection in Catalonia, Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Prevalence of hepatitis-C antibody seropositivity in healthy Egyptian children and four high risk groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

The "C" of viral hepatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Hepatitis C virus kinetics during and immediately after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540902998271

10.1080/00365540902998271

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference